Researchers are exploring various approaches to target KRAS mutations in cancer, including combination therapies and new inhibitors. Studies have investigated the use of trametinib, imatinib, and other treatments to overcome limitations of current KRAS-targeted therapies. The field of KRAS-targeted cancer therapies is actively being researched, with multiple preclinical models and analyses being conducted to understand the molecular mechanisms and potential therapeutic implications.